Drug Profile
AG 018
Alternative Names: AG018Latest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator CRS Bio
- Developer CRS Bio; Precigen Inc
- Class Antiallergics; Bacteria
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rhinosinusitis
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Rhinosinusitis in USA (Intranasal)
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
- 05 Oct 2018 Preclinical trials in Rhinosinusitis in USA (Intranasal) (Intrexon pipeline, October 2018)